Sjogren's syndrome
Drug research and approvals for sjogren's syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 57 studies of sjogren's syndrome are recruiting on ClinicalTrials.gov, Health Canada has authorized 10 drug trials for it since 2013, and FDA has 1 approved and 2 open orphan designations naming it.
- Recruiting worldwide: 57
- Trials authorized in Canada: 10
- FDA orphan approvals: 1
- EU medicines: 0
Recruiting Now
Newest start dates first, of 57 recruiting on ClinicalTrials.gov ↗- Pain Phenotyping of Rheumatic Diseases - An Observational StudyNCT07829497 · Not reported · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · starts Nov 9, 2026
- A Study of ATG-201 in Adult Participants With Autoimmune DiseasesNCT07732309 · Phase 1 · Antengene Biologics Limited · starts Sep 26, 2026
- A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it…NCT07649265 · Phase 1 · Otsuka Pharmaceutical Development & Commercialization, Inc. · starts Sep 24, 2026
- A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's DiseaseNCT07737743 · Phase 2 · Novartis Pharmaceuticals · starts Aug 24, 2026
- A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic DiseasesNCT07712939 · Phase 1 · Candid Therapeutics · starts Jul 22, 2026
- Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With…NCT07621809 · Phase 3 · Novartis Pharmaceuticals · starts Jul 16, 2026
- Clinical Efficacy of Telitacicept in Sjögren's Disease With Interstitial Lung DiseaseNCT07843381 · Not reported · Peking University People's Hospital · starts May 1, 2026
- Explanatory Factors and Predictors of Fatigue in Patients With Sjögren's Disease: A 3-month Longitudinal StudyNCT07544394 · Not reported · Kahramanmaras Sutcu Imam University · starts Apr 20, 2026
- Evaluation of the Prevalence, and Immunological Characteristics of Small Fiber Neuropathy in Patients With Primary…NCT07917442 · Not applicable · Centre Hospitalier Universitaire, Amiens · starts Mar 31, 2026
- Fatigue in Sjögren's Syndrome: 3 Therapeutic StrategiesNCT06875102 · Not applicable · Centre Hospitalier Universitaire de Saint Etienne · starts Mar 24, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| Jun 4, 2026 | A randomized, double-blind, placebo-controlled, multicenter phase 2a/b study assessing the efficacy, safety and tolerability of ddy391 in participants with…DDY391 | Novartis Pharmaceuticals Corporation | Ongoing |
| May 21, 2026 | A 52 week, 2 arm randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of ianalumab in patients with sjogren's disease with a…VAY736 | Novartis Pharmaceuticals Corporation | Ongoing |
| Aug 19, 2025 | A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of imvt- 1402 in…IMVT-1402 | IMMUNOVANT SCIENCES GMBH | Ongoing |
| Jun 17, 2025 | A randomized, placebo-controlled, double-blind, multicenter phase 3 protocol to assess the efficacy and safety of nipocalimab in adults with moderate to severe…JNJ-80202135 (NIPOCALIMAB) | Johnson & Johnson | Ongoing |
| Nov 20, 2024 | A phase 3 randomized, double-blinded, placebo-controlled multicenter trial with open-label extension to evaluate the efficacy, safety, and tolerability of…EFGARTIGIMOD (ARGX-113) PH20 SC | argenx US, Inc. | Ongoing |
| Mar 25, 2024 | A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of dazodalibep in participants with sjogren's syndrome with…DAZODALIBEP (HZN-4920) | Amgen | Ongoing |
| Sep 19, 2023 | A randomized, double-blind 2-arm neptunus extension study to access the long-term safety and efficacy of ianalumab in patients with sjogren's syndromeVAY736 (IANALUMAB) | Novartis Pharmaceuticals Corporation | Ongoing |
| May 4, 2022 | A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active…VAY736 | Novartis Pharmaceuticals Corporation | Closed |
| Aug 17, 2020 | A randomized, double-blind, placebo-controlled, parallel-group study of the safety, tolerability, pharmacokinetics, and therapeutic efficacy of sar441344 in…SAR441344 | SANOFI-AVENTIS CANADA INC | Closed |
| Dec 20, 2019 | A 48-week, 6-arm, randomized, double-blind, placebo-controlled multicenter trial to assess the safety and efficacy of multiple cfz533 doses administered…CFZ533 (ISCALIMAB) | Novartis Pharmaceuticals Corporation | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first| Feb 11, 1998 | SalagenTreatment of dry mouth in patients with Sjogren's syndrome. | MGI Pharma, Inc. | Approved |
| May 15, 1989 | BromhexineTreatment of mild to moderate keratoconjunctivitis sicca in patients with Sjogren's syndrome. | Boehringer Ingelheim Pharmaceuticals, Inc. | Designated |
| Nov 9, 1988 | Cyclosporine ophthalmicTreatment of severe keratoconjunctivitis sicca associated with Sjogren's syndrome. | University Of Georgia | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA